Immunocore Holdings plc - ADR logo

IMCR

Immunocore Holdings plc - ADR

$50.5

Earnings Summary

Revenue
$22.47Mn
Net Profits
$-16.13Mn
Net Profit Margins
-71.76%

Highlights

Revenue:

Immunocore Holdings plc - ADR’s revenue jumped 171.75% since last year same period to $22.47Mn in the Q1 2022. On a quarterly growth basis, Immunocore Holdings plc - ADR has generated 240.88% jump in its revenue since last 3-months.

Net Profits:

Immunocore Holdings plc - ADR’s net profit jumped 44.46% since last year same period to $-16.13Mn in the Q1 2022. On a quarterly growth basis, Immunocore Holdings plc - ADR has generated 59.05% jump in its net profits since last 3-months.

Net Profit Margins:

Immunocore Holdings plc - ADR’s net profit margin jumped 79.56% since last year same period to -71.76% in the Q1 2022. On a quarterly growth basis, Immunocore Holdings plc - ADR has generated 87.99% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Immunocore Holdings plc - ADR post its latest quarter earnings

EPS Estimate Current Quarter
-85.74
EPS Estimate Current Year
-85.74

Highlights

EPS Estimate Current Quarter:

Immunocore Holdings plc - ADR’s earning per share (EPS) estimates for the current quarter stand at -85.74 - a -4.29% fall from last quarter’s estimates.

EPS Estimate Current Year:

Immunocore Holdings plc - ADR’s earning per share (EPS) estimates for the current year stand at -85.74.

Key Ratios

Key ratios of the Immunocore Holdings plc - ADR post its Q1 2022 earnings

Earning Per Share (EPS)
-37
Return on Assets (ROA)
-0.18
Return on Equity (ROE)
-0.47
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Immunocore Holdings plc - ADR’s earning per share (EPS) jumped 44.34% since last year same period to -37 in the Q1 2022. This indicates that the Immunocore Holdings plc - ADR has generated 44.34% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Immunocore Holdings plc - ADR’s return on assets (ROA) stands at -0.18.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Immunocore Holdings plc - ADR’s return on equity (ROE) stands at -0.47.

Dividend Per Share (DPS):

Immunocore Holdings plc - ADR declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-03-31
-85.74
-37
56.85%

Company Information

Immunocore is a late-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, infectious and autoimmune. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including five clinical stage programs in oncology and infectious disease, advanced pre-clinical programs in autoimmune disease and multiple earlier pre-clinical programs. Immunocore’s most advanced oncology therapeutic candidate, tebentafusp, has demonstrated an overall survival benefit in a randomized Phase 3 clinical trial in metastatic uveal melanoma, a cancer that has historically proven to be insensitive to other immunotherapies.

Organisation
Immunocore Holdings plc - ADR
Employees
2.02K